In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will New Drugs For Motor Symptoms Of Parkinson's Disease Deliver?

Executive Summary

Because of the severity of the disease and the unmet medical need, competition to develop more effective treatments for motor complications of Parkinson's disease is fierce. Biopharma companies are employing a variety of strategies including reformulating approved drugs via new delivery systems and developing first-in-class therapies, which although riskier scientifically may command higher prices and greater acceptance from payors.

You may also be interested in...

Parkinson’s Disease At A Crossroad: Deals And Emerging Therapeutics

The last five years have seen an explosion in novel approaches to Parkinson’s disease.

Building the New Generation of Drugs in Neurodegeneration

Neurodegenerative diseases have emerged as one of the toughest and potentially most attractive frontiers in specialty drug development. Companies interested in the NDD space have the option of pursuing several strategies: disease-modifying therapies, symptom management therapies, or a hybrid approach, in which symptom-modifying drugs provide near-term revenues but also have longer-term potential for disease modification. Given the extraordinary difficulty associated with producing a successful disease-modifying new therapy, drugs aimed at treating symptoms are likely to dominate the NDD space for years. Licensors are rewarding developers with promising symptom modification programs with attractive deals.

In Case You Missed It: China’s ‘Dual Circulation’ Policy, Fixing Safety Data ‘Overload,’ And More

We clean out your Thanksgiving inbox so you don't have to.

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts